Welcome to our dedicated page for VVY news (Ticker: VVY), a resource for investors and traders seeking the latest updates and insights on VVY stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect VVY's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of VVY's position in the market.
Vivoryon Therapeutics (Euronext Amsterdam: VVY) announced that its 2026 Annual General Meeting will take place on Tuesday, September 29, 2026, at 11:00 a.m. CEST at the Amsterdam offices of NautaDutilh N.V. The full agenda and related documents are available on Vivoryon’s website.
Vivoryon is a clinical-stage biotechnology company developing small molecule medicines for inflammatory and fibrotic kidney disorders, including its lead candidate varoglutamstat for diabetic kidney disease.
Vivoryon Therapeutics (Euronext Amsterdam: VVY) reported H1 2026 results with zero revenues and a net loss of EUR 3.4 million, improved from EUR 5.5 million in H1 2025, driven by lower research and development and general and administrative expenses.
Cash and cash equivalents were EUR 2.4 million at June 30, 2026, down from EUR 5.6 million at year-end 2025, with total equity at EUR 1.6 million. The company maintains guidance that existing cash will fund operations into Q4 2026, but continuation beyond that and initiation of a planned Phase 2b diabetic kidney disease (DKD) trial depend on additional financing and/or partnerships.
Vivoryon is in advanced term sheet negotiations for a potential licensing agreement for varoglutamstat in kidney disease and reports an independent assessment by a specialist kidney investor. Phase 2 data from VIVIAD and VIVA-MIND showed statistically significant kidney function (eGFR) improvements, supported by new preclinical and mechanistic findings presented at WCN 2026.
Vivoryon Therapeutics (Euronext Amsterdam: VVY) announced it will report H1 2026 financial results and business updates for the period ended June 30, 2026 on August 6, 2026, followed by a public conference call and webcast. The company also plans to hold its 2026 Annual General Meeting at the end of September 2026.
Vivoryon Therapeutics (Euronext Amsterdam: VVY) reported Q1 2026 results and a kidney disease pipeline update. Varoglutamstat showed statistically significant eGFR improvements in two Phase 2 studies, with pronounced effects in elderly patients with diabetes, supporting a planned Phase 2b study in stage 3b/4 DKD, subject to new funding or partnerships.
Q1 2026 R&D and G&A each were EUR 0.9 million, and net loss was EUR 1.8 million. Cash and cash equivalents were EUR 4.0 million on March 31, 2026. Vivoryon reconfirmed guidance that existing cash should fund operations into Q4 2026, while actively pursuing strategic partnering and additional financing.
Vivoryon Therapeutics (VVY), a clinical-stage company developing small molecule medicines for inflammatory and fibrotic disorders focused on kidney diseases, will publish its Q1 2026 financial results for the period ended March 31, 2026 on Thursday, June 11, 2026.
The next financial and business update conference call/webcast is planned with the H1 2026 results, anticipated in August.
Vivoryon Therapeutics (Euronext: VVY) reported full-year 2025 results and a business update on April 23, 2026. Key highlights: varoglutamstat showed consistent eGFR benefit in two Phase 2 studies; a U.S. composition-of-matter patent runs through 2044; private placement raised €5.1M; cash of €5.6M; runway into Q4 2026.
The company plans a focused Phase 2b in stage 3b/4 DKD subject to funding or partnership and continues preclinical and MOA work supporting QPCT/L inhibition.
Vivoryon Therapeutics (Euronext: VVY) will report its full year 2025 financial results and business updates on April 23, 2026. The company will host a public conference call and webcast on April 23, 2026 at 3:00 pm CEST / 9:00 am EDT.
Investors can download the report and access the live audio webcast from Vivoryon’s investor website. Telephone participation requires pre-registration to receive dial-in details; attendees are advised to join 15 minutes early.
Vivoryon Therapeutics (Euronext: VVY) announced management will attend the Van Lanschot Kempen Life Sciences Conference on April 16, 2026 in Amsterdam.
Attendee: Julia Neugebauer, PhD, COO. The participation signals management engagement with investors and analysts at the event.
Vivoryon Therapeutics (Euronext: VVY) presented new analyses at the World Congress of Nephrology (March 28, 2026) reinforcing glutaminyl cyclases as targets in diabetic kidney disease (DKD). Phase 2 data from VIVIAD and VIVA-MIND showed consistent eGFR benefits, stronger effects in elderly patients with diabetes, and supportive DKD mouse-model improvements.
The company said these translational results support further development of varoglutamstat for patients with diabetes and more advanced chronic kidney disease stages.
Vivoryon Therapeutics (Euronext: VVY) announced management will attend and present at several medical and investor conferences in early 2026. Scheduled events include 1x1s around J.P. Morgan Healthcare Conference in San Francisco on Jan 12–14, 2026, the UBS European Healthcare Conference in London on Mar 3–4, 2026, and the World Congress of Nephrology (WCN) in Yokohama on Mar 28–31, 2026. The company focuses on small‑molecule therapies for inflammatory and fibrotic kidney diseases. For investor meetings contact: IR@vivoryon.com. A link to WCN is provided for conference details.